[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study

20260 citationsJournal Articlehybrid Open Access

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 27, Issue 4, pp. 470-479

Field-Weighted Citation Impact: 0.00